144 related articles for article (PubMed ID: 21639946)
1. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
[TBL] [Abstract][Full Text] [Related]
2. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
Moyer TP; O'Kane DJ; Baudhuin LM; Wiley CL; Fortini A; Fisher PK; Dupras DM; Chaudhry R; Thapa P; Zinsmeister AR; Heit JA
Mayo Clin Proc; 2009 Dec; 84(12):1079-94. PubMed ID: 19955245
[TBL] [Abstract][Full Text] [Related]
3. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients.
Xu Q; Zhang S; Wu C; Xiong Y; Niu J; Li F; Zhu J; Shen L; Zhu B; Xing Q; He L; Chen L; Li M; Li H; Ge J; Qin S
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e105-e111. PubMed ID: 33958549
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
[TBL] [Abstract][Full Text] [Related]
5. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
Ferder NS; Eby CS; Deych E; Harris JK; Ridker PM; Milligan PE; Goldhaber SZ; King CR; Giri T; McLeod HL; Glynn RJ; Gage BF
J Thromb Haemost; 2010 Jan; 8(1):95-100. PubMed ID: 19874474
[TBL] [Abstract][Full Text] [Related]
6. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
Botton MR; Bandinelli E; Rohde LE; Amon LC; Hutz MH
Br J Clin Pharmacol; 2011 Sep; 72(3):442-50. PubMed ID: 21320153
[TBL] [Abstract][Full Text] [Related]
7. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.
Fohner AE; Robinson R; Yracheta J; Dillard DA; Schilling B; Khan B; Hopkins S; Boyer B; Black J; Wiener H; Tiwari HK; Gordon A; Nickerson D; Tsai JM; Farin FM; Thornton TA; Rettie AE; Thummel KE
Pharmacogenet Genomics; 2015 Jul; 25(7):343-353. PubMed ID: 25946405
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
[TBL] [Abstract][Full Text] [Related]
9. Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients.
Zhang S; Zhao M; Zhong S; Niu J; Zhou L; Zhu B; Su H; Cao W; Xing Q; Yan H; Han X; Fu Q; Li Q; Chen L; Yang F; Zhang N; Wu H; He L; Qin S
Pharmacogenet Genomics; 2024 Jun; 34(4):105-116. PubMed ID: 38470454
[TBL] [Abstract][Full Text] [Related]
10. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
[No Abstract] [Full Text] [Related]
11. Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies.
Zhao Z; Zhao F; Wang X; Liu D; Liu J; Zhang Y; Hu X; Zhao M; Tian C; Dong S; Jin P
Clin Pharmacokinet; 2023 Jun; 62(6):819-833. PubMed ID: 37273173
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
Horne BD; Lenzini PA; Wadelius M; Jorgensen AL; Kimmel SE; Ridker PM; Eriksson N; Anderson JL; Pirmohamed M; Limdi NA; Pendleton RC; McMillin GA; Burmester JK; Kurnik D; Stein CM; Caldwell MD; Eby CS; Rane A; Lindh JD; Shin JG; Kim HS; Angchaisuksiri P; Glynn RJ; Kronquist KE; Carlquist JF; Grice GR; Barrack RL; Li J; Gage BF
Thromb Haemost; 2012 Feb; 107(2):232-40. PubMed ID: 22186998
[TBL] [Abstract][Full Text] [Related]
13. Population variation in VKORC1 haplotype structure.
Marsh S; King CR; Porche-Sorbet RM; Scott-Horton TJ; Eby CS
J Thromb Haemost; 2006 Feb; 4(2):473-4. PubMed ID: 16420583
[No Abstract] [Full Text] [Related]
14. Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population.
Harikrishnan S; Koshy L; Subramanian R; Sanjay G; Vineeth CP; Nair AJ; Nair GM; Sudhakaran PR
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S110-S115. PubMed ID: 30595241
[TBL] [Abstract][Full Text] [Related]
15. A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme.
D'Ambrosio RL; D'Andrea G; Cafolla A; Faillace F; Margaglione M
J Thromb Haemost; 2007 Jan; 5(1):191-3. PubMed ID: 17059426
[No Abstract] [Full Text] [Related]
16. Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
Ndadza A; Muyambo S; Mntla P; Wonkam A; Chimusa E; Kengne AP; Ntsekhe M; Dandara C
J Thromb Haemost; 2021 Dec; 19(12):2957-2973. PubMed ID: 34382722
[TBL] [Abstract][Full Text] [Related]
17. The largest prospective warfarin-treated cohort supports genetic forecasting.
Wadelius M; Chen LY; Lindh JD; Eriksson N; Ghori MJ; Bumpstead S; Holm L; McGinnis R; Rane A; Deloukas P
Blood; 2009 Jan; 113(4):784-92. PubMed ID: 18574025
[TBL] [Abstract][Full Text] [Related]
18. Association of warfarin dose with genes involved in its action and metabolism.
Wadelius M; Chen LY; Eriksson N; Bumpstead S; Ghori J; Wadelius C; Bentley D; McGinnis R; Deloukas P
Hum Genet; 2007 Mar; 121(1):23-34. PubMed ID: 17048007
[TBL] [Abstract][Full Text] [Related]
19. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Asiimwe IG; Zhang EJ; Osanlou R; Krause A; Dillon C; Suarez-Kurtz G; Zhang H; Perini JA; Renta JY; Duconge J; Cavallari LH; Marcatto LR; Beasly MT; Perera MA; Limdi NA; Santos PCJL; Kimmel SE; Lubitz SA; Scott SA; Kawai VK; Jorgensen AL; Pirmohamed M
Clin Pharmacol Ther; 2020 Jun; 107(6):1420-1433. PubMed ID: 31869433
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
